The economics of reproducibility in preclinical research

PLoS Biology

Volumn 13, Issue 6, 2015, Pages 1-9

  Freedman, Leonard P ^a   Cockburn, Iain M ^b   Simcoe, Timothy S ^b,c  

^a Global Biological Standards Institute   (United States)

^b BOSTON UNIVERSITY   (United States)

^c Council of Economic Advisers ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CLINICAL RESEARCH; DATA ANALYSIS; DRUG INDUSTRY; DRUG RESEARCH; FINANCIAL MANAGEMENT; GOVERNMENT; INFORMATION PROCESSING; INVESTMENT; LABORATORY TEST; METHODOLOGY; QUALITY CONTROL; RELIABILITY; REPRODUCIBILITY; STATISTICAL SIGNIFICANCE; SYSTEMATIC ERROR; UNITED STATES; ECONOMICS; MEDICAL RESEARCH; STANDARDS;

BIOMEDICAL RESEARCH; REPRODUCIBILITY OF RESULTS;

EID: 84934323188     PISSN: 15449173     EISSN: 15457885     Source Type: Journal    
DOI: 10.1371/journal.pbio.1002165     Document Type: Article

References (34)

1. Collins FS, Tabak LA (2014) NIH plans to enhance reproducibility. Nature 505: 612-613. PMID: 24482835
2. Begley CG, Ioannidis JP (2015) Reproducibility in Science: improving the standard for basic and preclinical research. Circ Res 116: 116-126. doi: 10. 1161/CIRCRESAHA. 114. 303819 PMID: 25552691
3. Macleod MR, Michie S, Roberts I, Dirnagl U, Chalmers I, et al. (2014) Biomedical research: increasing value, reducing waste. Lancet 383: 101-104. doi: 10. 1016/S0140-6736(13)62329-6 PMID: 24411643
4. Freedman LP, Gibson MC (2015) The impact of preclinical irreproducibility on drug development. Clin Pharmacol Therap 97: 16-18. doi: 10. 1002/cpt. 9 PMID: 25670378
5. Hartshorne JK, Schachner A (2012) Tracking replicability as a method of post-publication open evaluation. Front Comput Neurosci 6: 1-13. doi: 10. 3389/fncom. 2012. 00001 PMID: 22291635
6. Begley CG, Ellis LM (2012) Drug development: raise standards for preclinical cancer research. Nature 483: 531-533. doi: 10. 1038/483531a PMID: 22460880
7. Prinz F, Schlange T, Asadullah K (2011) Believe it or not: how much can we rely on published data on potential drug targets? Nat Rev Drug Discov 10: 712-712. doi: 10. 1038/nrd3439-c1 PMID: 21892149
8. Vasilevsky NA, Brush MH, Paddock H, Ponting L, Tripathy SJ, et al. (2013) On the reproducibility of science: unique identification of research resources in the biomedical literature. PeerJ 1: e148. doi: 10. 7717/peerj. 148 PMID: 24032093
9. Glasziou P, Meats E, Heneghan C, Shepperd S (2008) What is missing from descriptions of treatment in trials and reviews? BMJ 336: 1472-1474. doi: 10. 1136/bmj. 39590. 732037. 47 PMID: 18583680
10. Christakis DA, Zimmerman FJ (2013) Rethinking reanalysis. JAMA 310: 2499-2500. doi: 10. 1001/ jama. 2013. 281337 PMID: 24346985
11. Steward O, Popovich PG, Dietrich WD, Kleitman N (2012) Replication and reproducibility in spinal cord injury research. Exp Neurol 233: 597-605. doi: 10. 1016/j. expneurol. 2011. 06. 017 PMID: 22078756
12. Kimmelman J, Mogil JS, Dirnagl U (2014) Distinguishing between exploratory and confirmatory preclinical research will improve translation. PLoS Biol 12: e1001863. doi: 10. 1371/journal. pbio. 1001863 PMID: 24844265
13. GBSI (2013) The Case for Standards in Life Science Research: Seizing Opportunities at a Time of Critical Need. Washington, D. C.: Global Biological Standards Institute (GBSI). 41 p.
14. Ioannidis JP, Greenland S, Hlatky MA, Khoury MJ, Macleod MR, et al. (2014) Increasing value and reducing waste in research design, conduct, and analysis. Lancet 383: 166-175. doi: 10. 1016/S0140- 6736(13)62227-8 PMID: 24411645
15. Sena ES, van der Worp HB, Bath PM, Howells DW, Macleod MR (2010) Publication bias in reports of animal stroke studies leads to major overstatement of efficacy. PLoS Biol 8: e1000344. doi: 10. 1371/ journal. pbio. 1000344 PMID: 20361022
16. Freedman LP, Inglese J (2014) The increasing urgency for standards in basic biologic research. Cancer Res 74: 1-6.
17. Manski CF (2003) Partial Identification of Probability Distributions. In: Manski CF, editor. Springer Series in Statistics New York, New York, USA: Springer International Publishing AG. pp. 178.
18. Chakma J, Sun GH, Steinberg JD, Sammut SM, Jagsi R (2014) Asia's ascent-global trends in biomedical R&D expenditures. N Engl J Med 370: 3-6. doi: 10. 1056/NEJMp1311068 PMID: 24382062
19. AAAS (2013) AAAS Report XXXVIII: Research and Development FY 2014. Washington, DC, USA: American Association for the Advancement of Science (AAAS). 315 p.
20. Battelle (2013) 2014 Global R&D Funding Forecast. Columbus, Ohio, USA: Battelle. 36 p.
21. Stern AM, Casadevall A, Steen RG, Fang FC (2014) Financial costs and personal consequences of research misconduct resulting in retracted publications. Elife 3: e02956. doi: 10. 7554/eLife. 02956 PMID: 25124673
22. GunnW(2014) Reproducibility: fraud is not the big problem. Nature 505: 483. doi: 10. 1038/505483f PMID: 24451534
23. PhRMA (2013) 2013 Biopharmaceutical Research Industry Profile. Washington, DC, USA: Pharmaceutical Research and Manufacturers of America (PhRMA). 78 p.
24. Roth KA, Cox AE (2015) Science isn't science if it isn't reproducible. Am J Pathol 185: 2-3. doi: 10. 1016/j. ajpath. 2014. 11. 001 PMID: 25529794
25. Landis SC, Amara SG, Asadullah K, Austin CP, Blumenstein R, et al. (2012) A call for transparent reporting to optimize the predictive value of preclinical research. Nature 490: 187-191. doi: 10. 1038/ nature11556 PMID: 23060188
26. Baker D, Lidster K, Sottomayor A, Amor S (2014) Two years later: journals are not yet enforcing the ARRIVE guidelines on reporting standards for pre-clinical animal studies. PLoS Biol 12: e1001756. doi: 10. 1371/journal. pbio. 1001756 PMID: 24409096
27. Manolagas SC, Kronenberg HM (2014) Reproducibility of results in pre-clinical studies: a perspective from the bone field. J Bone Miner Res.
28. Furman JL, Stern S (2011) Climbing atop the shoulders of giants: the impact of institutions on cumulative research. Am Econ Rev 101: 1933-1963.
29. Lorsch JR, Collins FS, Lippincott-Schwartz J (2014) Cell Biology. Fixing problems with cell lines. Science 346: 1452-1453. doi: 10. 1126/science. 1259110 PMID: 25525228
30. Hughes P, Marshall D, Reid Y, Parkes H, Gelber C (2007) The costs of using unauthenticated, overpassaged cell lines: how much more data do we need? Biotechniques 43: 575, 577-578, 581-572 passim. PMID: 18072586
31. Buehring GC, Eby EA, Eby MJ (2004) Cell line cross-contamination: how aware are mammalian cell culturists of the problem and how to monitor it? In Vitro Cell Dev Biol Anim 40: 211-215. PMID: 15638703
32. Farrell J, Simcoe T (2012) Four Paths to Compatibility. In: Peitz M, Waldfogel J, editors. The Oxford Handbook of the Digital Economy. New York, New York, USA: Oxford University Press. pp. 34-58.
33. Ostrom E (1990) Governing the Commons: The Evolution of Institutions for Collective Action. New York, New York, USA: Oxford University Press. 298 p.
34. Berte LM, Daley AT (2014) Understanding the Cost of Quality in the Laboratory; A Report. Wayne, Pennsylvania, USA: Clinical Laboratory Standards Institute (CLSI). QMS20-R QMS20-R 94 p.